Literature DB >> 33163278

Evaluation of determinants for age disparities in the survival improvement of colon cancer: results from a cohort of more than 486,000 patients in the United States.

Fa Chen1,2, Fei Wang1,3, Christina E Bailey4, Harvey J Murff5, Jordan D Berlin6, Xiao-Ou Shu1, Wei Zheng1.   

Abstract

Over the past two decades, elderly colon cancer patients experienced less improvement in survival than their younger counterparts, yet the contributing factors remain unknown. We aimed to evaluate factors that may contribute to the age disparity of survival improvement among patients with colon cancer. Using data from the National Cancer Database, we identified patients diagnosed with colon cancer between 2004 and 2012 with follow-up data up to 2017. The hazard ratios (HR) and 95% confidence intervals (CI) for 5-year OS associated with study variables were estimated using multivariable Cox regression. Among 486,284 patients included in this study, elderly patients (aged ≥75) had a lower adherence to National Comprehensive Cancer Network (NCCN) treatment guidelines (% of non-adherence: 45.3%) than younger patients (aged <50, 19.3%; P<0.001). After adjusting for demographics, access to care and clinical characteristics, compared with patients diagnosed between 2004 and 2006, younger and older patients diagnosed between 2010 and 2012 experienced 16% (HR: 0.84, 95% CI: 0.81-0.88) and 6% (HR: 0.94, 95% CI: 0.93-0.95) reductions in mortality (P for interaction=1.42×10-5), respectively. After an additional adjustment for guideline adherence status, no significant difference in the improvement of survival was noted (P for interaction=0.17). The association patterns were similar regardless of tumor stage, race, and high comorbidity scores (all P for interaction>0.05). Several patient-related factors were identified in association with noncompliance to NCCN guidelines, including comorbidity status. However, over 60% of noncompliance elderly patients had a Charlson comorbidity score of 0. The observed age disparity in survival improvement among colon cancer patients was primarily explained by a slower improvement in adherence to NCCN treatment guidelines in elderly than younger patients. Many older adults were not receiving recommended therapies despite minimal comorbidities. Our findings call for measures to increase adherence to treatment guidelines among elderly patients to improve survival. AJCR
Copyright © 2020.

Entities:  

Keywords:  Colon cancer; elderly populations; guideline adherence; survival improvement

Year:  2020        PMID: 33163278      PMCID: PMC7642646     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  30 in total

1.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

2.  Adjuvant treatment for elderly patients with stage III colon cancer in the southern Netherlands is affected by socioeconomic status, gender, and comorbidity.

Authors:  V E P P Lemmens; A H van Halteren; M L G Janssen-Heijnen; G Vreugdenhil; O J Repelaer van Driel; J W W Coebergh
Journal:  Ann Oncol       Date:  2005-04-07       Impact factor: 32.976

3.  Impact of guideline changes on use or omission of radiation in the elderly with early breast cancer: practice patterns at National Comprehensive Cancer Network institutions.

Authors:  Beryl McCormick; Rebecca A Ottesen; Melissa E Hughes; Sara H Javid; Seema A Khan; Joanne Mortimer; Joyce C Niland; Jane C Weeks; Stephen B Edge
Journal:  J Am Coll Surg       Date:  2014-06-06       Impact factor: 6.113

4.  Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials.

Authors:  Charles D Blanke; Brian M Bot; David M Thomas; Archie Bleyer; Claus-Henning Kohne; Matthew T Seymour; Aimery de Gramont; Richard M Goldberg; Daniel J Sargent
Journal:  J Clin Oncol       Date:  2011-06-06       Impact factor: 44.544

5.  Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers: Results From the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010.

Authors:  Chenjie Zeng; Wanqing Wen; Alicia K Morgans; William Pao; Xiao-Ou Shu; Wei Zheng
Journal:  JAMA Oncol       Date:  2015-04       Impact factor: 31.777

Review 6.  The impact of comorbidity on cancer and its treatment.

Authors:  Diana Sarfati; Bogda Koczwara; Christopher Jackson
Journal:  CA Cancer J Clin       Date:  2016-02-17       Impact factor: 508.702

7.  Ovarian cancer in the United States: contemporary patterns of care associated with improved survival.

Authors:  William A Cliby; Matthew A Powell; Noor Al-Hammadi; Ling Chen; J Philip Miller; Phillip Y Roland; David G Mutch; Robert E Bristow
Journal:  Gynecol Oncol       Date:  2014-10-29       Impact factor: 5.482

8.  Chemotherapy Use and Survival Among Young and Middle-Aged Patients With Colon Cancer.

Authors:  Janna Manjelievskaia; Derek Brown; Katherine A McGlynn; William Anderson; Craig D Shriver; Kangmin Zhu
Journal:  JAMA Surg       Date:  2017-05-01       Impact factor: 14.766

9.  Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer.

Authors:  Arnold L Potosky; Linda C Harlan; Richard S Kaplan; Karen A Johnson; Charles F Lynch
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

10.  Does young age influence the prognosis of colorectal cancer: a population-based analysis.

Authors:  Andrew McKay; Jeniva Donaleshen; Ramzi M Helewa; Jason Park; Debrah Wirtzfeld; David Hochman; Harminder Singh; Donna Turner
Journal:  World J Surg Oncol       Date:  2014-12-02       Impact factor: 2.754

View more
  1 in total

1.  Survival Nomogram for Metastasis Colon Cancer Patients Based on SEER Database.

Authors:  Qinwen Tai; Wei Xue; Mengying Li; Shuli Zhuo; Heng Zhang; Fa Fang; Jinhui Zhang
Journal:  Front Genet       Date:  2022-02-09       Impact factor: 4.599

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.